Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report) dropped 4.8% on Wednesday . The stock traded as low as $4.75 and last traded at $4.95. 1,726 shares traded hands during trading, an increase of 433% from the average daily volume of 324 shares. The stock had previously closed at $5.20.
Starpharma Trading Up 9.1%
The company has a fifty day simple moving average of $4.85 and a 200-day simple moving average of $4.29.
About Starpharma
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
Featured Stories
- Five stocks we like better than Starpharma
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
